JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Telatinib (formerly BAY57-9352) is an orally bioavailable multi-kinase (e.g. VEGFR, PDGFR) inhibitor with potential antineoplastic activity. It inhibits VEGFR2/3, c-Kit and PDGFRalpha with IC50 values of 6 nM/4 nM, 1 nM and 15 nM, respectively. Telatinib was developed by Bayer company to reverse chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.
References: Clin Cancer Res. 2008 Jun 1; 14(11):3470-6; Br J Cancer. 2008 Nov 18; 99(10):1579-85.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!